TY - JOUR
T1 - Tissue sites of degradation of high density lipoprotein apolipoprotein A-IV in rats
AU - Dallinga-Thie, G. M.
AU - van 't Hooft, F. M.
AU - van Tol, A.
PY - 1986
Y1 - 1986
N2 - The in vivo metabolism of high density lipoprotein (HDL), labeled by incorporation of 125I-apolipoprotein (apo) A-IV, was studied in the rat and compared with the metabolism of HDL labeled with 131I-apo A-I. The 125I-apo A-IV labeled HDL was obtained by adding small amounts of radioiodinated apo A-IV to rat serum, followed by separation of the different lipoprotein fractions by chromatography on 6% agarose columns in order to avoid "stripping" of apolipoproteins by ultracentrifugation. Under both in vitro and in vivo conditions, the 125I-apo A-IV remained an integral component of HDL and was not exchanged to other lipoproteins, including the "free" apo A-IV fraction. The serum half-life, measured at between 8 and 28 hours after intravenous injection of labeled HDL, was 8.5 +/- 0.5 hours for HDL apo A-IV and 10.2 +/- 0.7 hours for HDL apo A-I. The tissue sites of catabolism of HDL apo A-IV and HDL apo A-I were analyzed in the "leupeptin-model." Only the kidneys and liver showed a significant leupeptin-dependent accumulation of radioactivity. At 4 hours after injection of 125I-apo A-IV/131I-apo A-I labeled HDL, 3.5% +/- 1.0% and 8.4% +/- 2.0% of HDL apo A-IV and 4.6% +/- 1.3% and 2.6% +/- 0.6% of the HDL apo A-I were accumulated in a leupeptin-dependent process in the kidneys and liver, respectively. Immunocytochemical studies revealed that the renal localization of apo A-IV was intracellular and confined to the epithelial cells of the proximal tubuli.(ABSTRACT TRUNCATED AT 250 WORDS)
AB - The in vivo metabolism of high density lipoprotein (HDL), labeled by incorporation of 125I-apolipoprotein (apo) A-IV, was studied in the rat and compared with the metabolism of HDL labeled with 131I-apo A-I. The 125I-apo A-IV labeled HDL was obtained by adding small amounts of radioiodinated apo A-IV to rat serum, followed by separation of the different lipoprotein fractions by chromatography on 6% agarose columns in order to avoid "stripping" of apolipoproteins by ultracentrifugation. Under both in vitro and in vivo conditions, the 125I-apo A-IV remained an integral component of HDL and was not exchanged to other lipoproteins, including the "free" apo A-IV fraction. The serum half-life, measured at between 8 and 28 hours after intravenous injection of labeled HDL, was 8.5 +/- 0.5 hours for HDL apo A-IV and 10.2 +/- 0.7 hours for HDL apo A-I. The tissue sites of catabolism of HDL apo A-IV and HDL apo A-I were analyzed in the "leupeptin-model." Only the kidneys and liver showed a significant leupeptin-dependent accumulation of radioactivity. At 4 hours after injection of 125I-apo A-IV/131I-apo A-I labeled HDL, 3.5% +/- 1.0% and 8.4% +/- 2.0% of HDL apo A-IV and 4.6% +/- 1.3% and 2.6% +/- 0.6% of the HDL apo A-I were accumulated in a leupeptin-dependent process in the kidneys and liver, respectively. Immunocytochemical studies revealed that the renal localization of apo A-IV was intracellular and confined to the epithelial cells of the proximal tubuli.(ABSTRACT TRUNCATED AT 250 WORDS)
U2 - https://doi.org/10.1161/01.ATV.6.3.277
DO - https://doi.org/10.1161/01.ATV.6.3.277
M3 - Article
C2 - 3085645
SN - 0276-5047
VL - 6
SP - 277
EP - 284
JO - Arteriosclerosis (Dallas, Tex.)
JF - Arteriosclerosis (Dallas, Tex.)
IS - 3
ER -